Emerging molecular markers of cancer

Nature Reviews Cancer

Volumn 2, Issue 3, 2002, Pages 210-219

  Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANNEXIN; BISULFITE; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOSINE; DNA; HERMES ANTIGEN; MOLECULAR MARKER; PROTEIN P53; SURVIVIN; TELOMERASE; URACIL;

CANCER; CANCER CLASSIFICATION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR MODEL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; BLOOD; GENETIC MARKER; GENETICS; MUTATION; NEOPLASM; SENSITIVITY AND SPECIFICITY;

DNA; GENETIC MARKERS; HUMANS; MUTATION; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 0036515416     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc755     Document Type: Review

References (95)

1. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
2. Feneley, M. R. & Partin, A. W. Diagnosis of localized prostate cancer: 10 years of progress. Curr. Opin. Urol. 10, 319-327 (2000).
3. Benson, A. B. et al. NCCN practice guidelines for colorectal cancer. Oncology 14, 203-212 (2000).
4. Olsen, O. & Gotzsche, P. C. Cochrane review on screening for breast cancer with mammography. Lancet 358, 1340-1342 (2001).
5. Pietras, R. J. et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10, 2435-2446 (1995).
6. Harris, L. N. et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J. Clin. Oncol. 19, 1698-1706 (2001).
7. Yancopoulos, G. D., Klagsbrun, M. & Folkman, J. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 93, 661-664 (1998).
8. Sawhney, R. S. et al. Differences in sensitivity of biological functions mediated by epidermal growth factor receptor activation with respect to endogenous and exogenous ligands. J. Biol. Chem. 277, 75-86 (2002).
9. Gold, P. & Freedman, S. O. Tests for carcinoembryonic antigen. Role in diagnosis and management of cancer. JAMA 234, 190-192 (1975).
10. Shapiro, B. et al. Determination of circulating DNA levels in patients with benign of malignant gastrointestinal disease. Cancer 51, 2116-2120 (1983).
11. Leon, S. A. et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646-650 (1977).
12. Anker, P., Lyautey, J., Lederrey, C. & Stroun, M. Circulating nucleic acids in plasma or serum. Clin. Chim. Acta 11, 143-146 (2001). References 10-12 establish and discuss the significance of the presence of free DNA in the serum of patients with cancer.
13. Sidransky, D. et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252, 706-709 (1991).
14. Sidransky, D. et al. Identification of RAS oncogene mutations in the stool of patients with curable colorectal tumors. Science 256, 102-105 (1992). References 13 and 14 establish the ability to detect oncogene mutations in body fluids.
15. Mills, N. E. et al. Detection of KRAS oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J. Natl Cancer Inst. 87, 1056-1060 (1995).
16. Tobi, M., Luo, F. C. & Ronai, Z. Detection of KRAS mutation in colonic effluent samples from patients without evidence of colorectal carcinoma. J. Natl Cancer Inst. 86, 1007-1010 (1994).
17. Dong, S. M. et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J. Natl Cancer Inst. 93, 858-865 (2001). References 15-17 use multiple genetic targets to identify cancer cells in stool DNA.
18. Ahlquist, D. A. et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119, 1219-1227 (2000).
19. Traverso, G. et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N. Engl. J. Med. 346, 311-320 (2002).
20. Jackson, P. E. et al. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res. 61, 33-35 (2001).
21. Sun, X., Hung, K., Wu, L., Sidransky, D. & Guo, B. Detection of tumor mutations in the presence of excess amounts of normal DNA. Nature Biotechnol. 20, 186-189 (2002).
22. Brennan, J. A. et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332, 429-435 (1995).
23. Hayashi, N. et al. Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res. 54, 3853-3856 (1994). References 22 and 23 establish the use of oncogene mutations in the staging of cancer.
24. Mao, L. et al. Microsatellite alterations as clonal markers for the detection of human cancer. Proc. Natl Acad. Sci. USA 21, 9871-9875 (1994).
25. Mao, L. et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 271, 659-662 (1996).
26. Steiner, G., Schoenberg, M. P., Linn, J. F., Mao, L. & Sidransky, D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Med. 3, 621-624 (1997).
27. Spafford, M. F. et al. Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. Clin. Cancer Res. 7, 607-612 (2001).
28. Nawroz, H. et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Med. 2, 1035-1037 (1996). References 25-28 highlight the use of microsatellite analysis in cancer detection.
29. Chen, X. Q. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nature Med. 2, 972-974 (1996).
30. Ahrendt, S. A. et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl Cancer Inst. 91, 332-339 (1999).
31. Medintz, I. L. et al. Loss of heterozygosity assay for molecular detection of cancer using energy-transfer primers and capillary array electrophoresis. Genome Res. 10, 1211-1218 (2000).
32. Hacia, J. G. et al. Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays. Nature Genet. 22, 164-167 (1999).
33. Baylin, S. B. & Herman, J. G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16, 168-174 (2000).
34. Merlo, A. et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1, 686-692 (1995).
35. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D. & Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821-9826 (1996). A method for detecting methylated markers by PCR.
36. Rosas, S. L. et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61, 939-942 (2001).
37. Belinsky, S. A. et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA 95, 11891-11896 (1998).
38. Palmisano, W. A. et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954-5958 (2000).
39. Esteller M. et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67-70 (1999).
40. Sanchez-Cespedes, M. et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60, 892-895 (2000).
41. Grady, W. M., Rajput, A., Lutterbaugh, J. D. & Markowitz, S. D. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 61, 900-902 (2001).
42. Kawakami, K. et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl Cancer Inst. 92, 1805-1811 (2000).
43. Usadel, H. et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 62, 371-375 (2002). References 42 and 43 highlight the use of quantitative methylation in cancer detection.
44. Esteller, M., Corn, P. G., Baylin, S. B. & Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225-3229 (2001). A comprehensive list of methylated genes in human cancer.
45. Jeronimo, C. et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93, 1747-1752 (2001).
46. Warburg, O., Geissler, A. W. & Lorenz, S. [On growth of cancer cells in media in which glucose is replaced by galactose]. Hoppe Seylers Z. Physiol. Chem. 348, 1686-1687 (1967).
47. Polyak, K. et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nature Genet. 20, 291-293 (1998).
48. Fliss, M. S. et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287, 2017-2019 (2000).
49. Sanchez-Cespedes, M. et al. Identification of a mononuclectide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res. 61, 7015-7019 (2001). References 47-49 address the identification of rnitochondrial DNA mutations in tumours and clinical samples.
50. Sherman, M. E. et al. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Cancer 81, 89-97 (1997).
51. Capone, R. B. et al. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin. Cancer Res. 11, 4171-4175 (2000).
52. Lo, Y. M. et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 59, 5452-5455 (1999).
53. Lo, Y. M. et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr vrus DNA. Cancer Res. 60, 6878-6881 (2000).
54. Datta, Y. H. et al. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J. Clin. Oncol. 12, 475-482 (1994).
55. Gerhard, M. et al. Specifc detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J. Clin. Oncol. 12, 725-729 (1994).
56. Krismann, M. et al. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J. Clin. Oncol. 13, 2769-2775 (1995).
57. Katz, A. E. et al. Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 75, 1642-1648 (1995).
58. Smith, B. et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338, 1227-1229 (1991).
59. Foss, A. J. et al. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br. J. Cancer 72, 155-159 (1995).
60. Brossart, P. et al. A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res. 55, 4065-4068 (1995).
61. Zippelius, A. et al. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J. Clin. Oncol. 15, 2701-2708 (1997).
62. Taback, B. et al. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical state of disease. Cancer Res. 61, 8845-8850 (2001). References 55-62 highlight the clinical issues that surround reverse transcriptase PCR detection of cancer cells.
63. Chu, E. et al. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol. Pharmacol. 39, 136-143 (1991).
64. Salonga, D. et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6, 1322-1327 (2000).
65. Ohara, K. et al. Utility of serum CA19-9 monitoring in preoperative radiotherapy for pancreatic cancer. Hepatogastroenterology 48, 859-863 (2001).
66. Slesak, B. et al. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA19-9. Cancer 89, 83-88 (2001).
67. Urgell, E. et al. Prospective evaluation of the contribution of KRAS mutational analysis and CA19.9 measurement to cytological diagnosis in patients with clinical suspicion of pancreatic cancer. Eur. J. Cancer 36, 2069-2075 (2000).
68. Canizares, F. et al. Preoperative values of CA15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol. 22, 273-281 (2001).
69. Sjostrom, J. et al. Serum tumour markers CA15-3, TPA, hCGβ and TATI in the monitoring of chemotherapy response in metastatic breast cancer. Scand. J. Clin. Lab. Invest. 61, 431-441 (2001).
70. Liefers, G. J. et al. Micrometastases and survival in stage II colorectal cancer. N. Engl. J. Med. 339, 223-228 (1998).
71. Rosell, R., Green, M. & Gumerlock, P. Advances in the treatment of non-small cell lung cancer: molecular markers take the stage. Semin. Oncol. 28, 28-34 (2001).
72. Wright, W. E., Shay, J. W. & Piatyszek, M. A. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res. 23, 3794-3795 (1995). This study decribes the TRAP protocol for measuring telomerase activity.
73. Nakamura, T. M. et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 277, 955-959 (1997).
74. Califano, J. et al. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res. 56, 5720-5722 (1996).
75. Yoshida, K. et al. Detection of telomerase activity in exfoliated cancer cells in colonic luminal washings and its related clinical implications. Br. J. Cancer 75, 548-553 (1997).
76. Yoshida, K. et al. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 79, 362-369 (1997).
77. Jassem, E. et al. Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance. Lung Cancer 31, 17-23 (2001).
78. Yamaguchi, K. et al. Circulating antibodies to p40(AIS) in the sera of respiratory tract cancer patients. Int. J. Cancer 89, 524-528 (2000).
79. Lubin, R. et al. Serum p53 antibodies as early markers of lung cancer. Nature Med. 1, 701-702 (1995).
80. Schena, M. et al. Parallel human genome analysis: microarray-based expression monitoring of 1,000 genes. Proc. Natl Acad. Sci. USA 93, 10614-10619 (1996).
81. Pollack, J. R. et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nature Genet. 23, 41-46 (1999).
82. Velculescu, V. E., Zhang, L., Vogelstein, B. & Kinzler, K. W. Senal analysis of gene expression. Science 270, 368-371 (1995).
83. Argani, P. et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 7, 3862-3868 (2001).
84. Ahrendt, S. A. et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc. Natl Acad. Sci. USA 96, 7382-7387 (1999).
85. Hanash, S. 2-D or not 2-D: is there a future for 2-D gels in proteomics? Insights from the York proteomics meeting. Proteomics 1, 635-637 (2001).
86. Paweletz, C. P., Liotta, L. A. & Petricoin, E. F. New technologies for biomarker analysis of prostate cancer progression: laser capture microdissection and tissue proteomics. Urology 57, 160-163 (2001).
87. Bichsel, V. E., Liotta, L. A. & Petricoin, E. F. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J. 7, 69-78 (2001).
88. Wall, D. B. et al. Isoelectric focusing nonporous RP HPLC: a two-dimensional liquid-phase separation method for mapping of cellular proteins with identification using MALDI-TOF mass spectrometry. Anal. Chem. 72, 1099-1111 (2000).
89. Verma, M., Wright, G. L. Jr, Hanash, S. M., Gopal-Srivastava, R. & Srivastava, S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann. NY Acad. Sci. 945, 103-115 (2001).
90. Madoz-Gurpide, J. et al. Protein based microarrays: a tool for probing the proteome of cancer cells and tissues. Proteomics 10, 1279-1287 (2001).
91. Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 859, 572-577 (2002). The use of proteomics to detect protein patterns in the serurn of patients with ovarian cancer.
92. Le Naour, F. et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin. Cancer Res. 7, 3328-3335 (2001).
93. Brichory. F., Beer, D., LeNaour, F., Giordano, T. & Hanash, S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 61, 7908-7912 (2001).
94. Srinivas, P. R., Srivastava, S., Hanash, S. & Wright, G. L. Jr. Proteomics in early detection of cancer. Clin. Chem. 41, 1901-1911 (2001).
95. Rawlings, C. J. & Seads, D. B. Computational gene discovery and human disease. Curr. Opin. Genet. Dev. 7, 416-423 (1997).